Pharmaceuticals Global On demand · 24-48h

Global NAD+ Health Products Market Strategic Research Report

Global NAD+ Health Products Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global NAD+ Health Products Market
$5642025
15.7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: NMNContent <98%, NMNContent ≥98%

By Application: Health Care Products, Beauty Products, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: GeneHarbor, Niagen Bioscience, Mirailab Bioscience Inc. (Shinkowa Pharmaceutical), Herbalmax, EffePharm, Kingdomway, NOMON Co., Ltd. (Teijin), CELFULL, Bontac, Genex Formulas, EZZ, Maac10 Formulas, Elysium Health

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 115 pages
Market size 2025
$564
Million USD
Forecast CAGR
15.7%
2025-2032
Forecast 2032
$1565.4
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

Overview

Scope of the Report

The global NAD+ Health Products market size is predicted to grow from US$ 564 million in 2025 to US$ 1,540 million in 2032; it is expected to grow at a CAGR of 15.7% from 2026 to 2032.

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells. It plays a crucial role in various biological processes, including energy metabolism, DNA repair, and gene expression. Some people are interested in NAD+ enhancers, which are substances or compounds that may support or increase the levels of NAD+ in the body.

Strong Market Growth Driven by Aging Population and Longevity Demand

The NAD+ booster capsule market is expected to maintain strong growth as global populations age and consumer awareness of longevity, cellular health, and metabolic wellness increases. Capsules remain the most commercially scalable and accessible format, making them the preferred product type for retail brands. Demand is expanding rapidly in North America, Europe, Japan, and China, driven by rising interest in anti-aging science and the shift toward preventive healthcare.

Scientific Validation and Ingredient Innovation Accelerate Adoption

Future development will be shaped by increasing clinical research on NMN, NR, and other NAD+ precursors, which is improving consumer trust and regulatory acceptance. Innovation in stabilization technology, sustained-release capsules, and enhanced-bioavailability formulations (such as liposomal or microencapsulated NAD+ boosters) is expected to differentiate brands and raise product efficacy. Companies are also developing novel precursor combinations to expand the biological pathways for NAD+ synthesis.

Regulatory Standardization and Quality Compliance Will Become Critical

As NAD+ boosters gain popularity, more stringent global regulations are emerging to ensure safety, purity, and label accuracy—especially in the U.S., EU, and China. The industry is shifting toward pharmaceutical-grade manufacturing, third-party testing, and validated human trials. Brands able to meet future compliance standards and provide transparent clinical data will dominate premium segments, while lower-quality manufacturers may be pressured out of the market.

Expansion into Personalized Nutrition and Integrated Health Ecosystems

Future growth will increasingly come from personalized supplementation, digital health integration, and subscription-based models. NAD+ booster capsules will be combined with biomarker testing, mitochondrial support formulas, gut-health products, and AI-driven health monitoring platforms. Partnerships with longevity clinics, anti-aging centers, and wellness programs will help capsules evolve from stand-alone supplements into components of broader metabolic and cellular-health ecosystems.

This report presents a comprehensive overview of the global NAD+ Health Products market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • NMNContent <98%
  • NMNContent ≥98%

Segment by Form

  • Powder
  • Liquid
  • Others

Segment by Ingestion Method

  • Oral Type
  • Non-oral Type

Segment by Application

  • Health Care Products
  • Beauty Products
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global NAD+ Health Products market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Health Care Products, Beauty Products, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global NAD+ Health Products Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 15.7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$564
2025
Forecast
$1565.4
2032
CAGR
15.7%
2025–2032
Regions
5
global
Key companies
GeneHarborNiagen BioscienceMirailab Bioscience Inc. (Shinkowa Pharmaceutical)HerbalmaxEffePharmKingdomwayNOMON Co.Ltd. (Teijin)
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
NMNContent <98%NMNContent ≥98%
By Application
Health Care ProductsBeauty ProductsOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 NMNContent <98%
  • 3.1.3 NMNContent ≥98%
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Health Care Products
  • 4.1.3 Beauty Products
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 GeneHarbor
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Niagen Bioscience
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Mirailab Bioscience Inc. (Shinkowa Pharmaceutical)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Herbalmax
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 EffePharm
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Kingdomway
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 NOMON Co., Ltd. (Teijin)
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 CELFULL
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Bontac
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Genex Formulas
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 EZZ
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Maac10 Formulas
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Elysium Health
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global NAD+ Health Products market?
The global NAD+ Health Products market is estimated at US$ 564 million in 2025 (base year) and is projected to reach US$ 1.54 billion by 2032.
What is the forecast CAGR for the NAD+ Health Products market?
The market is expected to grow at a CAGR of 15.7% from 2026 to 2032, expanding from US$ 564 million in 2025 to US$ 1.54 billion in 2032, roughly 2.7 times its base-year value.
What is NAD+ Health Products?
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells. It plays a crucial role in various biological processes, including energy metabolism, DNA repair, and gene expression. Some people are interested in NAD+ enhancers, which are substances or compounds that may support or increase the levels of NAD+ in the body.
How is the NAD+ Health Products market segmented by type?
By type, the market is segmented into NMNContent <98% and NMNContent ≥98%.
What are the key applications of NAD+ Health Products?
Key applications covered include Health Care Products, Beauty Products and Others.
Which companies are profiled in the NAD+ Health Products market report?
Key players profiled include GeneHarbor, Niagen Bioscience, Mirailab Bioscience Inc. (Shinkowa Pharmaceutical), Herbalmax, EffePharm, Kingdomway, NOMON Co., Ltd. (Teijin) and CELFULL, among 13 companies covered in total.
What geographies does the NAD+ Health Products market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for NAD+ Health Products?
Strong Market Growth Driven by Aging Population and Longevity Demand
Who should buy the NAD+ Health Products market report?
The report is intended for manufacturers and solution providers, distributors and end users in Health Care Products, Beauty Products and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the NAD+ Health Products market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.